Duchenne Muscular Dystrophy (DMD) Clinical Trial
Background: Duchenne muscular dystrophy (DMD) is an X chromosome recessive hereditary
disease and mainly characterized by progressive muscle weakness and atrophy. Glucocorticoid
is the only proven effective medicine,while side effects limit its use. Recent studies have
shown that the vascular density in the DMD patients' muscle is decreased,so muscle are in
ischemic and anoxic. Remote ischemic preconditioning(RIPC) can improve the capable of
resistanting ischemia and hypoxia and maybe a potential therapy for DMD patients.
Methods: 100 patients (aged 2 to 6 years)will be divided into two groups(treatment and
control groups) randomly. Treatment group will receive an RIPC stimulus (inflation of a
blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals) while
control group will receive a similar stimulus (inflation of a blood pressure cuff on the
bilateral thighs to 40 mm Hg for four 5-minute intervals). Serum kinase level ,Blood levels
of myoglobin, Evaluation of motor function(Four steps test;6-minute walking test) and MRI of
lower limbs）at 0 days, 3 days, 3months ,6months.
Purpose：
1. To evaluate the safety and tolerability of remote ischemic preconditioning for DMD
patients
2. To identify the effectiveness of remote ischemic preconditioning for DMD patients.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02814019 -
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
|
Phase 3 | |
| Completed |
NCT01478022 -
To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20
|
Phase 1 | |
| Completed |
NCT00654784 -
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Withdrawn |
NCT02036463 -
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT02255552 -
Study of Eteplirsen in DMD Patients
|
Phase 3 | |
| Completed |
NCT01982695 -
Cardiomyopathy in DMD: Lisinopril vs. Losartan
|
N/A | |
| Recruiting |
NCT05516745 -
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
|
N/A | |
| Completed |
NCT02420379 -
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
| Active, not recruiting |
NCT05135663 -
Extension Study of NS-089/NCNP-02 in DMD
|
Phase 2 | |
| Completed |
NCT01380964 -
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
|
N/A | |
| Completed |
NCT05990608 -
Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT04322357 -
Twice Weekly Steroids and Exercise as Therapy for DMD
|
Phase 2 | |
| Not yet recruiting |
NCT06392724 -
A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
|
Early Phase 1 | |
| Completed |
NCT01540409 -
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Terminated |
NCT04184882 -
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
| Terminated |
NCT04254172 -
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT05524883 -
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
Phase 1/Phase 2 | |
| Completed |
NCT01761292 -
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
|
Phase 1/Phase 2 |